AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...
In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...
The 11th Cell Biology Industry Conference (CBIC) opened in Beijing, attracting more than 3,000 guests from clinical research ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Hosted on MSN10h
Global regenerative medicine market to grow by $70.11b by 2028It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...
Discover a study that aims to customise CIC profiles for patients, providing insights into which stages of the cycle are most ...
Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback